A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (NCT06220604)
77242113PSO3004
This trial is Currently recruiting
Registration number NCT06220604
Program & service
This trial is being run with the Specialty Medicine service, and as part of the Dermatology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Johannes S Kern
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.